Cargando…

Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count

The most common adverse reactions to rituximab are infusion-related reactions (IRR). We evaluated the efficacy of split dosing the first rituximab infusion over two days to reduce IRR incidence in patients with hematological cancer and a high lymphocyte count. This is a retrospective observational s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plante, Maude, Garneau, Laurence, Laprise-Lachance, Magali, Lemieux, Pierre, Dorval, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534443/ https://www.ncbi.nlm.nih.gov/pubmed/34677267 http://dx.doi.org/10.3390/curroncol28050349

Ejemplares similares

Acute Myocardial Infarction after First Dose of Rituximab Infusion
por: Gogia, Ajay, et al.
Publicado: (2014)

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
por: Courville, Jocelyn, et al.
Publicado: (2021)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
por: Bryan, Jeffrey, et al.
Publicado: (2011)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
por: Castro, Januario E., et al.
Publicado: (2009)

Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high‐dose methylprednisolone, revisited
por: Vagos Mata, Ana, et al.
Publicado: (2021)

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
por: Svenningsson, Anders, et al.
Publicado: (2015)

Acute Respiratory Distress Syndrome after Rituximab Infusion
por: Montero, Alberto J., et al.
Publicado: (2005)

Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy
por: Suzuki, Manabu, et al.
Publicado: (2022)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
por: Pileckyte, Regina, et al.
Publicado: (2019)

A Case of Coronary Vasospasm after Repeat Rituximab Infusion
por: Ke, Calvin, et al.
Publicado: (2015)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
por: Pérez‐Persona, Ernesto, et al.
Publicado: (2023)

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2019)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

Brain Abscess following Rituximab Infusion in a Patient with Pemphigus Vulgaris
por: Al-Harbi, Talal M., et al.
Publicado: (2015)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
por: Gentile, M, et al.
Publicado: (2010)

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia
por: Šimkovič, Martin, et al.
Publicado: (2015)

The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion
por: Lamanna, William C, et al.
Publicado: (2017)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019)

RELAPSE AND REMITTING COVID-19 INFECTIONS IN AN IMMUNOSUPPRESSED PATIENT ON CHRONIC RITUXIMAB INFUSIONS
por: GREWAL, SAHIB, et al.
Publicado: (2021)

B lymphocyte-typing for prediction of clinical response to rituximab
por: Brezinschek, Hans-Peter, et al.
Publicado: (2012)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

Successful desensitization to high dose rituximab for a child with nephrotic syndrome – The first report in the literature
por: Kakleas, Konstantinos, et al.
Publicado: (2021)

Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients
por: Tessarin, Giulio, et al.
Publicado: (2023)

Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases
por: Pan, Shan, et al.
Publicado: (2019)

Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab
por: Ibrahim, Uroosa, et al.
Publicado: (2017)

Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil
por: Lin, Mike, et al.
Publicado: (2020)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Sampling Site Matters When Counting Lymphocyte Subpopulations
por: Ogunjimi, Benson, et al.
Publicado: (2012)

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
por: Evertsson, Björn, et al.
Publicado: (2020)

Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study
por: Thonhoff, Jason R., et al.
Publicado: (2018)

Management of retroperitoneal hemorrhage compressing the inferior vena cava in a patient with a renal transplant: A case report
por: Fontaine, Elizabeth, et al.
Publicado: (2020)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
por: Lurati, Alfredomaria, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qls9nd9o6a2i07oo5k8j1k8nll